Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Malignant Solid Neoplasm
- Sponsor
- Thomas Jefferson University
- Enrollment
- 26
- Locations
- 1
- Primary Endpoint
- Number of medical related problem (MRP)s identified by the pharmacist through retrospective chart reviews (Phase I)
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
This trial studies how well pharmacist-led transitions of care works in the outpatient oncology infusion center for patients with solid tumor. Having a pharmacist in the outpatient oncology infusion center may help to identify and correct medical related problems and improve overall patient and staff satisfaction. Patients receiving education may benefit from gaining a better understanding of their antineoplastic therapy. Understanding the side effects associated with the therapy may also help patients better be prepared to manage any adverse effects they may experience.
Detailed Description
PRIMARY OBJECTIVE: I. To demonstrate the effectiveness of a clinical oncology pharmacist in the outpatient infusion center through education, and the identification and correction of medication related problem (MRP)s. SECONDARY OBJECTIVE: I. To evaluate overall patient and staff satisfaction with the added clinical oncology pharmacy education. EXPLORATORY OBJECTIVE: I. Estimate the cost avoidance utilizing the pharmacy services provided in the prospective trial. OUTLINE: PHASE I: Patients' medical records are reviewed. PHASE II: Patients receive pharmacist-led education on antineoplastic therapies including what to expect during infusion, general drug facts, common adverse effects, side effect management, and when to contact provider. After completion of study, patients are followed up periodically.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Solid tumor diagnosis
- •Starting day 1 of new antineoplastic infusion
- •English speaking (and/or English-speaking primary caregiver/proxy)
Exclusion Criteria
- •Metastasis to the brain and/or central nervous system (CNS) with evidence of impaired cognition
- •Severe cognitive impairment including dementia with inability to consent to the study
Outcomes
Primary Outcomes
Number of medical related problem (MRP)s identified by the pharmacist through retrospective chart reviews (Phase I)
Time Frame: Up to 1 year
MRPs will be assigned to a specific category and the total number of MRPs in each category will be recorded. Categories include but are not limited to: incorrect dose, therapeutic duplication, drug not indicated, drug interaction, monitoring recommendation, drug allergy, or potential for adverse event.
Percent of MRPs corrected as a result of the clinical oncology pharmacist services (Phase II)
Time Frame: Up to 1 year
In phase 2 (prospective) MRPs will also be recorded and categorized, but in addition the outcomes relating to each MRP pharmacist intervention will be recorded. MRPs found by the pharmacist will be communicated to the patient's oncologist or primary care provider, and the pharmacist will follow-up to see if changes were made.
Secondary Outcomes
- Patient and provider satisfaction with the pharmacist-led education(Up to 1 year)